/PRNewswire/ Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that Molecular.
Overexpressed in Solid TumorsADC Currently in a First-in-Human Study NIJMEGEN, Netherlands, April 12, 2023 /PRNewswire/ Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical
Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521 · BYON3521 Targets c-MET, Widely Overexpressed in Solid Tumors· Therapy Uses Proprietary Technologies Designed to Enhance Efficacy.
BYON3521 Targets c-MET, Widely Overexpressed in Solid TumorsTherapy Uses Proprietary Technologies Designed to Enhance Efficacy and SafetyNIJMEGEN, Netherlands, Aug. 25, 2022 /PRNewswire/
/PRNewswire/ Byondis B.V., an independent, clinical stage Dutch biopharmaceutical company creating precision medicines, today announced that the first.